小摩日前参与药明康德的2025年投资者日，适逢美国总统特朗普宣布计划自10月1日起对进口品牌药及 专利药征收100%关税，除非相关药厂已在美国动工兴建生产设施。小摩预期这次药品关税政策对药明 康德等中国CDMO企业不会构成直接影响，因客户通常负责支付关税，而且药明康德正在扩充其美国产 能，以满足客户对本地化生产的需求。 智通财经APP获悉，摩根大通发布研报称，继续列药明康德(02359)为中国CXO行业的首选股，指出该 公司是中国收入规模最大的合同研究开发与生产组织，看好其业务基本面，认为小分子CRDMO领域竞 争相对温和，同时药明TIDES业务增长动力持续强劲，维持"增持"评级，目标价138港元。 ...

摩根大通发表研究报告指，日前参与药明康德2025年投资者日，适逢美国总统特朗普宣布计划自10月1 日起对进口品牌药及专利药征收100%关税，除非相关药厂已在美国动工兴建生产设施。摩通预期今次 药品关税政策对药明康德等中国CDMO企业不会构成直接影响，因客户通常负责支付关税，而且药明康 德正在扩充其美国产能，以满足客户对本地化生产的需求。 摩通继续列药明康德为中国CXO行业的首选股，指出该公司是中国收入规模最大的合同研究开发与生 产组织，看好其业务基本面，认为小分子CRDMO领域竞争相对温和，同时药明TIDES业务增长动力持 续强劲，维持"增持"评级，目标价138港元。 ...

2025 年 9 月 29 日 招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 行业、公司点评 全球市场观察 招银国际研究部 邮件：research@cmbi.com.hk | 环球主要股市上日表现 | | | | | --- | --- | --- | --- | | | 收市价 | | 升跌（%） | | | | 单日 | 年内 | | 恒生指数 | 26,128 | -1.35 | 30.25 | | 恒生国企 | 9,303 | -1.49 | 27.62 | | 恒生科技 | 6,195 | -2.89 | 38.65 | | 上证综指 | 3,828 | -0.65 | 14.21 | | 深证综指 | 2,471 | -1.54 | 26.22 | | 深圳创业板 | 3,152 | -2.60 | 47.16 | | 美国道琼斯 | 46,247 | 0.65 | 8.70 | | 美国标普 500 | 6,644 | 0.59 | 12.96 | | 美国纳斯达克 | 22,484 | 0.44 | 16.43 | | 德国 DAX | 23,739 | 0.87 | 19.24 ...

Core Viewpoint - The announcement of a 100% tariff on all branded/patented drugs by Trump starting in October is expected to have limited impact on China's innovative drug industry chain, with no excessive concerns warranted [1] Group 1: Impact on Innovative Drugs - Most Chinese innovative drugs that are currently being exported have either established production capacity in the U.S. or have outsourced production to local CMO companies [1] - The majority of domestic innovative drugs are exported using a business development (BD) model, which mitigates the impact of the tariff [1] Group 2: Impact on CXO Sector - The export products in the CXO sector primarily consist of raw materials and biological raw liquids, which are not affected by the new tariff; the proportion of finished dosage forms exported is low [1] - The investment timeline for multinational corporations (MNCs) to build factories in China will take time, leading to limited direct impact on CXO orders in the short term [1] - Long-term policy changes may influence the pace of factory construction by MNCs [1] Group 3: Upcoming Catalysts - The ESMO conference will take place in mid to late October, with a focus on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995) that are expected to release significant data [1] - The results of medical insurance negotiations and the first version of the commercial insurance innovative drug directory are expected to be announced in October-November [1] Group 4: Mid to Long-term Recommendations - Recommended stocks in the innovative drug sector include 3SBio (01530) and Eucure Biopharma-B (06996), which have rich short-term catalysts and their valuations do not yet reflect the core value of major products [2] - Companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered undervalued with clear long-term growth logic [2] - In the CXO sector, WuXi AppTec (02268) is highlighted as a leading player benefiting from high downstream demand and improving financing conditions [2]

交银国际研究 每日晨报 2025 年 9 月 29 日 今日焦点 医药行业 特朗普对进口创新药加征关税，但实际影响或 有限，建议逢低布局 丁政宁 Ethan.Ding@bocomgroup.com 特朗普宣布 10 月起对所有品牌/专利药征收 100%关税。美国总统特朗普 通过社交媒体宣布自 10 月 1 日起，将对所有进口的品牌药或受专利保护 的成品药及制剂征收 100%关税，除非该制造商正在美国境内建设生产设 施（包括动工或在建）。此关税政策不适用于仿制药、生物类似药及原 料药/API 等中间体。 对中国创新药产业链影响有限，无需过度担忧：1）创新药：当前自主出 海品种多在美自建产能或已将生产外包给美国本土 CMO，而大部分国产 创新药出海采用 BD 模式。2）CXO：出口产品以原料药/生物药原液为主， 暂不受影响，制剂/成品药出口比例较低，下游 MNC 客户投资建厂尚需 时日，短期内对 CXO 订单直接冲击有限，长期来看政策变化也可能影响 其建厂节奏。总体而言，表面上此次美国加征药品关税短期冲击集中于 依赖海外生产之跨国药企、倒逼其在美国建厂，但整体覆盖范围有限、 对于中国医药产业链的整体影响或可控，与 ...

Core Viewpoint - Kanglong Chemical is recognized as a leading global drug research and development enterprise with a full-process, integrated, international, and multi-therapy approach [1] Company Summary - The company’s laboratory services, small molecule CDMO, clinical CRO, and large molecule and cell gene therapy services are expected to have ample growth momentum and broad growth space [1] - Kanglong Chemical is on a path to becoming a global integrated research and production service giant [1] Industry Summary - Given the growth prospects of the company and the global competitive advantages of China's CXO industry, a higher valuation level is deemed appropriate [1] - The report suggests a target price of 47.73 yuan based on a 40 times PE for 2026, and a target price of 39.34 Hong Kong dollars based on a 30 times PE for 2026 [1] - The report initiates coverage with a "recommend" rating [1]

交银国际研究 消息快报 医药行业 2025 年 9 月 26 日 医药 2025 年 9 月 26 日 特朗普对进口创新药加征关税，但实际影响或有限，建议逢低布局 丁政宁 Ethan.Ding@bocomgroup.com (852) 3766 1834 诸葛乐懿 Gloria.Zhuge@bocomgroup.com (852) 3766 1845 此报告最后部分的分析师披露、商业关系披露和免责声明为报告的一部分，必须阅读。 下载本公司之研究报告，可从彭博信息：BOCM 或 https://research.bocomgroup.com 特朗普宣布10 月起对所有品牌/专利药征收100%关税。美国总统特朗普于 2025 年 9 月 25 日通过社交媒体宣布，自 10 月 1 日起，将对所有进口的品 牌药（branded）或受专利保护（patented）的成品药及制剂征收 100%关 税，除非该制造商正在美国境内建设生产设施（已动工或在建的工厂可申 请豁免）。此关税政策不适用于仿制药、生物类似药及原料药/API 等中间 体，其进口仍可能免受关税影响。 对中国创新药产业链影响有限，无需过度担忧：1）创新药：当前 ...

Core Insights - The report from Cinda Securities indicates a significant recovery in domestic innovative drug financing, with a total of $7.75 billion in financing from January to August 2025, representing a year-on-year increase of approximately 89% [1] - The secondary market financing reached $5.135 billion, showing a remarkable year-on-year growth of about 304% [1] - The CXO industry is experiencing an improvement in supply-demand dynamics, with leading companies expected to re-enter an expansion phase due to recovering market demand [2] Group 1: CXO Industry Overview - The CXO industry operates on a "water seller" business model, closely tied to the financing of the biopharmaceutical sector [1] - Domestic innovative drug financing has begun to recover, aided by a rebound in the Hong Kong stock market and business development (BD) opportunities abroad [1] - The overall supply-demand relationship in the CXO sector is improving, with leading companies like WuXi AppTec and WuXi Biologics planning significant capital expenditures for 2025, indicating confidence in market recovery [2] Group 2: CDMO Sector Insights - CDMO leaders are experiencing marginal improvements in performance since Q4 2024, driven by high overseas revenue and a recovery in overseas investment and financing demand [3] - The unique business model of CDMOs allows for project pipeline expansion, which can sustain performance growth even amid challenges in new project signings [3] - The demand for new molecules such as peptides and ADCs is robust, prompting CDMO leaders to strategically position themselves in these emerging markets [3] Group 3: CRO Sector Insights - The CRO sector shows performance divergence among leading companies, with some beginning to recover, likely due to their specific business characteristics and operational cycles [4] - Most CRO companies are seeing improvements in order volumes, which serve as a leading indicator for future performance [4] - The slight increase in the price of experimental monkeys suggests a potential recovery in preclinical CRO demand, highlighting the importance of companies that control these scarce resources [4] Group 4: Recommended Companies - Key companies to watch include WuXi AppTec, WuXi Biologics, WuXi AppTec's ADC business, and others, with their valuations falling within reasonable ranges based on their business characteristics and market trends [5][6] - Specific highlights include WuXi AppTec's TIDES business, WuXi Biologics' project reserves, and the resilience of Sunlight Nuohuo's CRO business [6]

Core Viewpoint - The Hang Seng Healthcare Index fell by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Recommendations - The report suggests focusing on companies with significant data releases at the upcoming ESMO conference in mid to late October, specifically mentioning Kangfang Biotech (09926), Kelun-Biotech (06990), and Rongchang Biotech (09995) [1] - The importance of timing and stock selection has increased following a broad rise in the innovative drug sector, with recommendations to gradually build positions during market corrections [1] Group 3: Sector Focus - For the innovative drug sector, the report highlights companies such as 3SBio (01530) and Eucure Biopharma-B (06996) as having rich short-term catalysts and undervalued core products, while companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are noted as significantly undervalued with clear long-term growth logic [1] - In the CXO sector, the report points to leading companies benefiting from high downstream demand and marginal recovery in financing, specifically mentioning WuXi AppTec (02268) [1]

Core Viewpoint - The Hang Seng Healthcare Index declined by 1.4% this week, underperforming the market, with internet medicine, CXO, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Since September, the proportion of domestic holdings through the Hong Kong Stock Connect has remained stable, while foreign holdings have slightly decreased since mid-year [1] - Both domestic and foreign investors continue to increase their positions in innovative pharmaceutical companies, indicating a consistent long-term strategy [1] Group 2: Investment Opportunities - Domestic investors are focusing on rebound opportunities, while foreign investors are increasing positions in innovative drug targets with high long-term potential and current cost-effectiveness [1] - The innovative drug guarantee model is gradually taking shape, which is expected to alleviate challenges such as hospital access and reimbursement difficulties for companies [1] Group 3: Upcoming Events - The ESMO conference will be held in mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995) that are expected to release significant data [1] Group 4: Stock Recommendations - The importance of timing and stock selection has increased after a broad rise in the innovative drug sector, with recommendations to gradually build positions during sector pullbacks [1] - Specific recommendations include: 1. Innovative drugs: 3SBio (01530), Eucure Biopharma-B (06996) with rich short-term catalysts and undervalued long-term growth logic [1] 2. CXO: Leaders in high-demand segments benefiting from improved financing conditions, such as WuXi AppTec (02268) [1]